Richard Sykes (biochemist)
|Born||Richard Brook Sykes
7 August 1942
|Thesis||Studies on the B-lactamases of Pseudomonas aeruginosa (1972)|
Sir Richard Brook Sykes, DSc, FRS, FMedSci, (born 7 August 1942) is chairman of the Royal Institution, Imperial College Healthcare and Chancellor of Brunel University. Sykes also chairs the UK Stem Cell Foundation and is Non-executive director of Lonza AG. Previously, Sykes was an executive director at GlaxoSmithKline and rector of Imperial College London, UK. Sir Richard was the Senior Independent Director and non-executive Deputy Chairman and Chairman of the Remuneration Committee of Eurasian Natural Resources Corporation (ENRC) until June 2011.
Sykes was educated at Queen Elizabeth College where he graduated with a Bachelor of Science degree in Microbiology. He went on to study for a PhD in Microbial Biochemistry from the University of Bristol in 1972 with thesis on B-lactamases of Pseudomonas aeruginosa.
Until 2001, Sir Richard Sykes was chairman of GlaxoSmithKline and president of the British Association for the Advancement of Science. In December 2007 he was appointed Independent Non-Executive Director at Eurasian Natural Resources Corporation (ENRC). In October 2008, Sykes accepted Farad Azima's invitation to join the NetScientific Group as the non-executive Chairman. In 2009, Sykes accepted the position as executive chairman of Toumaz Technology Ltd.
Sykes's tenure was not without controversy.
- In 2004 he spearheaded an abortive attempt to merge Imperial College with University College London.
- He supported the lifting of the £3,000 cap on tuition fees and instead allowing the universities to set fees at anything up to £10,000, a proposal opposed by many student-representing societies. This was long before UK coalition government reforms that allow £9,000 fees to be charged from 2011.
- His predecessor at Imperial had brokered a merger with the University of London's agricultural college, Wye College. Sykes overturned a promise to keep Agricultural Sciences taught at Wye at the end of 2004. By 2005 Imperial announced plans to create a non-food crops and biomass fuels research centre, anchoring a major housing development on College land. The true extent of these plans, which would have seen the small academic village become a town, were kept secret from the public by Imperial, Ashford Borough Council and Kent County Council. Plans collapsed in June 2006 after media leaks and loss of their potential industry partner, and Imperial then renounced all development aspirations for the campus and surrounding land. The Save.Wye campaign described Sykes as "...an avaricious businessman posing as an academic" after the full extent of the plans were revealed. A book by David Hewson  details the entire episode.
- In March 2006 his salary became the centre of attention amongst Imperial College staff and students after the students' union newspaper, FELIX, published a front page article highlighting how much he was paid. Sir Richard received a salary £305,000 a year, the second highest among university principals after Professor Laura Tyson, dean of the London Business School.
On 1 July 2008, he was succeeded as Rector of Imperial College by Professor Roy Anderson.
Sir Richard joined Adcurata Cultural Change Advisory Board in September 2012 to advise on the pharmaceutical and healthcare markets.
Awards and honours
Sykes holds a number of honorary degrees, including ones from the universities of Birmingham, Brunel, Cranfield, Edinburgh, Hertfordshire, Huddersfield, Hull, Leeds, Leicester, Madrid, Newcastle, Nottingham, Sheffield Hallam, Sheffield, Strathclyde, Surrey, Warwick and Westminster.
Sykes was elected a Fellow of the Royal Society in 1997. His nominations reads
|“||Richard Sykes is distinguished both as an experimental scientist and as a major force in the British pharmaceutical industry. He has, in his own right, made important experimental contributions to microbiology, of which the best known are his work on B-lactamases, and the discovery of the first monocyclic B-lactam antibiotic, aztreonam. The latter was not an accidental finding or simply the outcome of routine screening. Sykes was personally responsible for the development of imaginative new micro-screens of much greater sensitivity than those in use in the antibiotic industry at the time, and these ultra-sensitive screens enabled him to detect compounds present in trace amounts that were not detectable by standard methods. Aztreonam proved to be a major advance in the treatment of gram-negative infections. In 1986 Sykes rejoined Glaxo where he is now Deputy Chairman and Chief Executive of Glaxo Holdings plc. His influence within Glaxo and the pharmaceutical industry generally has been marked by a firm conviction of the overriding importance of good fundamental science, and this has found expression not only in the massive development of Glaxo R and D, but also in the vigorous interaction of the company with the university sector in the United Kingdom. He also makes a significant positive contribution to national science policy. The case for the election of Richard Sykes as a general candidate is very strong.||”|
- Sir Richard Sykes DSc - 1994
- Richmond, M. H.; Sykes, R. B. (1973). "The β-Lactamases of Gram-Negative Bacteria and their Possible Physiological Role". Advances in Microbial Physiology Volume 9. Advances in Microbial Physiology 9. p. 31. doi:10.1016/S0065-2911(08)60376-8. ISBN 9780120277094.
- Sykes, R. B.; Cimarusti, C. M.; Bonner, D. P.; Bush, K.; Floyd, D. M.; Georgopapadakou, N. H.; Koster, W. H.; Liu, W. C.; Parker, W. L.; Principe, P. A.; Rathnum, M. L.; Slusarchyk, W. A.; Trejo, W. H.; Wells, J. S. (1981). "Monocyclic β-lactam antibiotics produced by bacteria". Nature 291 (5815): 489. doi:10.1038/291489a0. PMID 7015152.
- Datta, N; Hedges, R. W.; Shaw, E. J.; Sykes, R. B.; Richmond, M. H. (1971). "Properties of an R factor from Pseudomonas aeruginosa". Journal of bacteriology 108 (3): 1244–9. PMC 247211. PMID 4945193.
- Sykes, R. B.; Bonner, D. P.; Bush, K; Georgopapadakou, N. H. (1982). "Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria". Antimicrobial agents and chemotherapy 21 (1): 85–92. PMC 181833. PMID 6979307.
- Opposition ends Imperial and UCL merger dream, The Guardian 2002-11-18
- GlaxoSmithKline -- Lessons of a Failed Merger: Matthew Lynn
- New chair for science institution BBC News 2010-09-16
- Sir Richard Sykes appointed new Chair at Imperial College Healthcare NHS Trust
- Sir Richard Sykes appointed Chancellor of Brunel University
- ENRC Management
- Biography — Sir Richard Sykes
- "SYKES, Sir Richard (Brook)". Who's Who 2014, A & C Black, an imprint of Bloomsbury Publishing plc, 2014; online edn, Oxford University Press.(subscription required)
- Sykes, Richard Brook (1972). Studies on the B-lactamases of Pseudomonas aeruginosa (PhD thesis). University of Bristol.
- Bush, K.; Freudenberger, J. S.; Sykes, R. B. (1982). "Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria". Antimicrobial Agents and Chemotherapy 22 (3): 414. doi:10.1128/AAC.22.3.414. PMID 6982680.
- Richard Sykes (biochemist) from the Scopus bibliographic database
- NetScientific Group.
- Sir Richard Sykes: Rector 2001–08, Imperial College London, UK.
- David Hewson. 2007. Saved; How an English village fought for its survival and won. Leicester: Troublador Publishing
- http://savewye.wordpress.com/2007/04/06/the-principal-players-where-are-they-now/#more-352 Savewye.wordpress.com, 7 April 2007.
- Randeep Ramesh (26 May 2010). "NHS London chief Richard Sykes resigns in care review row". The Guardian. Retrieved 2010-05-27.
- "Advisory Council of the Campaign for Science and Engineering". Retrieved 2011-02-11.
- "Library and Archive Catalogue EC/1997/33 Sir Richard Brook". London: The Royal Society.
|Rector of Imperial College London
John Wakeham, Baron Wakeham
|Chancellor of Brunel University